Irritable bowel syndrome: Pathophysiology and (future) treatment options;Het prikkelbaredarmsyndroom: Pathofysiologie en (toekomstige) behandelingsmogelijkheden

Nederlands Tijdschrift voor Geneeskunde

Volumn 146, Issue 1, 2002, Pages 12-17

  Schryver, A M P ^a   Samsom, M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

KAPPA OPIATE RECEPTOR AGONIST; MUSCARINIC RECEPTOR BLOCKING AGENT; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SPASMOLYTIC AGENT;

AUTONOMIC NERVOUS SYSTEM; HUMAN; INTESTINE MOTILITY; IRRITABLE COLON; PATHOGENESIS; PATHOPHYSIOLOGY; PERCEPTION; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; TREATMENT PLANNING;

ANALGESICS, NON-NARCOTIC; BEHAVIOR THERAPY; COLONIC DISEASES, FUNCTIONAL; HUMANS; HYPNOSIS; MUSCARINIC ANTAGONISTS; PARASYMPATHOLYTICS; RECEPTORS, CHOLECYSTOKININ; RECEPTORS, OPIOID, KAPPA; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS;

EID: 0037021812     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. NHG-standaard prikkelbare darm syndroom (irritable bowel syndrome)
2. The epidemiology of functional gastrointestinal disorders in North America
3. The functional gastrointestinal disorders and the Rome II process
4. Functional bowel disorders and functional abdominal pain
5. Irritable bowel syndrome. Diagnosis in the managed care era
6. Identification of distinct upper and lower gastrointestinal symptom groupings in an urban population
7. The irritable bowel syndrome
8. Largescale ambulatory study of postprandial jejunal motility in irritable bowel syndrome
9. Intraluminal small intestinal pressure in normal patients and in patients with functional gastrointestinal disorders
10. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms
11. A pilot study of motility and tone of the left colon in patients with diarrhea due to functional disorders and dysautonomia
12. Impaired colonic motor response to cholinergic stimulation in patients with severe chronic idiopathic (slow transit type) constipation
13. Clinical evidence to support current therapies of irritable bowel syndrome
14. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome
15. Mebeverine (Duspatal) bij een prikkelbare darm?
16. Discovery & development of selective M3 antagonists for clinical use
17. Blocking effects of otilonium on Ca2+ channels and secretion in rat chromaffin cells
18. Colonic motility and gastric emptying in patients with irritable bowel syndrome. Effect of pretreatment with octylonium bromide
19. Effect of cisapride on the gastrointestinal transit of a solid meal in normal human subjects
20. Role of colonic motility in guiding therapy in patients with constipation
21. Effects of cisapride on QT interval in children
22. Idiopathic constipation: Too few stools and too little knowledge
23. Role of visceral afferent mechanisms in functional bowel disorders
24. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist
25. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome
26. Kappa opioid receptor agonists differentially inhibit two classes of rat spinal neurons excited by colorectal distention
27. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome
28. Altered rectal perception is a biological marker of patients with irritable bowel syndrome
29. Tolerance for rectosigmoid distention in irritable bowel syndrome
30. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy
31. The safety and efficacy of Alosetron, a 5-HT3 receptor antagonist, in female irritable bowel syndrome patients
32. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome
33. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone
34. Effect of leuprolide acetate in treatment of abdominal pain and nausea in premenopausal women with functional bowel disease
35. Effect of leuprolide acetate in patients with functional bowel disease. Longterm follow-up after double-blind, placebo-controlled study
36. Role of cholecystokinin in regulation of gastrointestinal motor functions
37. Effects of acute psychologic stress on small-intestinal motility in health and the irritable bowel syndrome
38. Psychological and physical stress induce differential effects on human colonic motility
39. Review article: An integrated approach to the irritable bowel syndrome
40. Irritable bowel syndrome and psychiatric illness
41. Is functional dyspepsia just a subset of the irritable bowel syndrome?
42. The effect of trimipramine in patients with the irritable bowel syndrome. A double-blind study
43. Symptom relief with amitriptyline in the irritable bowel syndrome
44. Pharmacologic treatment of the irritable bowel syndrome: A systematic review of randomized, controlled trials
45. A controlled trial of psychological treatment for the irritable bowel syndrome
46. Hypnotherapy in severe irritable bowel syndrome: Further experience
47. Potential pitfalls in the differential diagnosis of irritable bowel syndrome